45 CFR § 180 compliance
D · 65
This hospital published part of what § 180 requires.
●Machine-readable file published: assessment threshold met
●Gross / standard charges: assessment threshold met
●Discounted cash price: assessment threshold met
○Payer-specific negotiated rates: below assessment threshold
○Min / max negotiated charges: below assessment threshold
●Free, public, no login required: assessment threshold met
Procedures listed
2,910
Insurances with rates
55
CPT / HCPCS codes
2,711
Most expensive procedures (gross)
33882
$78,698
33882 - W/ CC Endovascular repair of the thoracic aorta by deployment of a branched endograft multip
Gross
$104,931
16296
$62,031
Rufinamide Level QST
Gross
$82,708
J9228
$39,117
ipilimumab 200 mg/40 mL Sol [TAHL]
Gross
$78,233
33270
$56,963
Ins/rep subq defibrillator
Gross
$75,950
0571T
$36,252
Insj/rplcmt icds ss eltrd
Gross
$72,503
33262
$29,378
Rmvl& replc pulse gen 1 lead
Gross
$58,756
33263
$27,446
Rmvl & rplcmt dfb gen 2 lead
Gross
$54,892
J1303
$25,867
ravulizumab 1100mg / 11mL Inj Sol [TAHL]
Gross
$51,734
C1822
$37,800
Gen, neuro, hf, rechg bat
Gross
$50,400
J9043
$23,610
cabazitaxel 60 mg/1.5 mL Sol [TAHL]
Gross
$47,220
J2350
$22,292
ocrelizumab 300 mg/10 mL Sol [TAHL]
Gross
$44,585
C1772
$31,952
Infusion pump, programmable
Gross
$42,603
33229
$21,179
Remv&replc pm gen mult leads
Gross
$42,358
37271
$31,150
37271 REVASC ENDOVASC FPVT ATHRC SF 1
Gross
$41,534
37273
$31,150
37273 REVSC ENDOVASC FPVT ATHRC CPLX 1
Gross
$41,534
37275
$31,150
37275 REVSC ENDOVASC FPVT ST ATHRC SF 1
Gross
$41,534
37277
$31,150
37277 REVSC ENDOVASC FPVT ST ATHR CPLX 1
Gross
$41,534
37284
$31,150
37284 REVASC ENDOVASC TPVT SF 1
Gross
$41,534
37286
$31,150
37286 REVASC ENDOVASC TPVT STENT CPLX 1
Gross
$41,534
37288
$31,150
37288 REVASC ENDOVASC TPVT ATHRC SF 1
Gross
$41,534
37290
$31,150
37290 REVASC ENDOVASC TPVT ATHRC CPLX 1
Gross
$41,534
37292
$31,150
37292 REVASC ENDOVASC TPVT ATHRC STENT SF 1
Gross
$41,534
37294
$31,150
37294 REVASC ENDOVASC TPVT ATHRC STENT CPLX 2
Gross
$41,534
C9733
$29,798
Non-ophthalmic fva
Gross
$39,730
C9766
$29,798
Revasc intra lithotrip-ather
Gross
$39,730
C9765
$29,798
Revasc intra lithotrip-stent
Gross
$39,730
C9774
$29,798
Revasc lithotr-ather tib/per
Gross
$39,730
C9767
$29,798
Revasc lithotrip-stent-ather
Gross
$39,730
C9775
$29,798
Revasc lith-sten-ath tib/per
Gross
$39,730
C1882
$29,083
Aicd, other than sing/dual
Gross
$38,777
33274
$18,290
Tcat insj/rpl perm ldls pm
Gross
$36,580
33249
$17,102
Insj/rplcmt defib w/lead(s)
Gross
$34,203
J9298
$16,329
nivolumab-relatlimab rmbw 240 mg-80 mg/20 mL Inj Sol [TAHL]
Gross
$32,658
C1721
$24,263
Aicd, dual chamber
Gross
$32,350
33230
$24,102
Insrt pulse gen w/dual leads
Gross
$32,136
33240
$24,102
Insrt pulse gen w/singl lead
Gross
$32,136
35602
$23,941
35602 - W/ CC Bypass graft, with other than vein; carotid-contralateral carotid
Gross
$31,922
J1628
$15,732
guselkumab 200 mg/20 mL Inj Sol [TAHL]
Gross
$31,464
C1722
$21,692
Aicd, single chamber
Gross
$28,922
J9042
$13,690
brentuximab vedotin 50 mg REC [TAHL]
Gross
$27,380
C1767
$19,969
Generator, neuro non-recharg
Gross
$26,625
37258
$19,673
37258 REVASC ENDOVASC IVT STENT SF 1
Gross
$26,231
37260
$19,673
37260 REVASC ENDOVASC IVT ST CPLX 1
Gross
$26,231
37262
$19,673
37262 - Intravascular lithotripsy(ies), iliac vascular territory
Gross
$26,231
37267
$19,673
37267 REVASC ENDOVASC FPVT STENT SF 1
Gross
$26,231
37269
$19,673
37269 REVASC ENDOVASC FPVT SF CPLX 1
Gross
$26,231
37280
$19,673
37280 REVASC ENDOVASC TPVT ANGIO SF 1
Gross
$26,231
37282
$19,673
37282 REVASC ENDOVASC TPVT CPLX EA
Gross
$26,231
37296
$19,673
37296 - REVASC ENDOVASC INFRAMALLEOLAR ANGIO SF 1
Gross
$26,231
37298
$19,673
37298 - REVASC ENDOVASC INFRAMALLEOLAR ANGIO CPLX 1
Gross
$26,231
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 33882 | 33882 - W/ CC Endovascular repair of the thoracic aorta by deployment of a branched endograft multip | $104,931 | $78,698 | — | — | 0 |
| 16296 | Rufinamide Level QST | $82,708 | $62,031 | — | — | 0 |
| J9228 | ipilimumab 200 mg/40 mL Sol [TAHL] | $78,233 | $39,117 | — | — | 0 |
| 33270 | Ins/rep subq defibrillator | $75,950 | $56,963 | — | — | 0 |
| 0571T | Insj/rplcmt icds ss eltrd | $72,503 | $36,252 | — | — | 1 |
| 33262 | Rmvl& replc pulse gen 1 lead | $58,756 | $29,378 | — | — | 2 |
| 33263 | Rmvl & rplcmt dfb gen 2 lead | $54,892 | $27,446 | — | — | 2 |
| J1303 | ravulizumab 1100mg / 11mL Inj Sol [TAHL] | $51,734 | $25,867 | — | — | 0 |
| C1822 | Gen, neuro, hf, rechg bat | $50,400 | $37,800 | — | — | 0 |
| J9043 | cabazitaxel 60 mg/1.5 mL Sol [TAHL] | $47,220 | $23,610 | — | — | 0 |
| J2350 | ocrelizumab 300 mg/10 mL Sol [TAHL] | $44,585 | $22,292 | — | — | 0 |
| C1772 | Infusion pump, programmable | $42,603 | $31,952 | — | — | 0 |
| 33229 | Remv&replc pm gen mult leads | $42,358 | $21,179 | — | — | 2 |
| 37271 | 37271 REVASC ENDOVASC FPVT ATHRC SF 1 | $41,534 | $31,150 | — | — | 0 |
| 37273 | 37273 REVSC ENDOVASC FPVT ATHRC CPLX 1 | $41,534 | $31,150 | — | — | 0 |
| 37275 | 37275 REVSC ENDOVASC FPVT ST ATHRC SF 1 | $41,534 | $31,150 | — | — | 0 |
| 37277 | 37277 REVSC ENDOVASC FPVT ST ATHR CPLX 1 | $41,534 | $31,150 | — | — | 0 |
| 37284 | 37284 REVASC ENDOVASC TPVT SF 1 | $41,534 | $31,150 | — | — | 0 |
| 37286 | 37286 REVASC ENDOVASC TPVT STENT CPLX 1 | $41,534 | $31,150 | — | — | 0 |
| 37288 | 37288 REVASC ENDOVASC TPVT ATHRC SF 1 | $41,534 | $31,150 | — | — | 0 |
| 37290 | 37290 REVASC ENDOVASC TPVT ATHRC CPLX 1 | $41,534 | $31,150 | — | — | 0 |
| 37292 | 37292 REVASC ENDOVASC TPVT ATHRC STENT SF 1 | $41,534 | $31,150 | — | — | 0 |
| 37294 | 37294 REVASC ENDOVASC TPVT ATHRC STENT CPLX 2 | $41,534 | $31,150 | — | — | 0 |
| C9733 | Non-ophthalmic fva | $39,730 | $29,798 | — | — | 0 |
| C9766 | Revasc intra lithotrip-ather | $39,730 | $29,798 | — | — | 1 |
| C9765 | Revasc intra lithotrip-stent | $39,730 | $29,798 | — | — | 2 |
| C9774 | Revasc lithotr-ather tib/per | $39,730 | $29,798 | — | — | 0 |
| C9767 | Revasc lithotrip-stent-ather | $39,730 | $29,798 | — | — | 1 |
| C9775 | Revasc lith-sten-ath tib/per | $39,730 | $29,798 | — | — | 0 |
| C1882 | Aicd, other than sing/dual | $38,777 | $29,083 | — | — | 0 |
| 33274 | Tcat insj/rpl perm ldls pm | $36,580 | $18,290 | — | — | 2 |
| 33249 | Insj/rplcmt defib w/lead(s) | $34,203 | $17,102 | — | — | 8 |
| J9298 | nivolumab-relatlimab rmbw 240 mg-80 mg/20 mL Inj Sol [TAHL] | $32,658 | $16,329 | — | — | 0 |
| C1721 | Aicd, dual chamber | $32,350 | $24,263 | — | — | 0 |
| 33230 | Insrt pulse gen w/dual leads | $32,136 | $24,102 | — | — | 0 |
| 33240 | Insrt pulse gen w/singl lead | $32,136 | $24,102 | — | — | 0 |
| 35602 | 35602 - W/ CC Bypass graft, with other than vein; carotid-contralateral carotid | $31,922 | $23,941 | — | — | 0 |
| J1628 | guselkumab 200 mg/20 mL Inj Sol [TAHL] | $31,464 | $15,732 | — | — | 0 |
| C1722 | Aicd, single chamber | $28,922 | $21,692 | — | — | 0 |
| J9042 | brentuximab vedotin 50 mg REC [TAHL] | $27,380 | $13,690 | — | — | 0 |
| C1767 | Generator, neuro non-recharg | $26,625 | $19,969 | — | — | 0 |
| 37258 | 37258 REVASC ENDOVASC IVT STENT SF 1 | $26,231 | $19,673 | — | — | 0 |
| 37260 | 37260 REVASC ENDOVASC IVT ST CPLX 1 | $26,231 | $19,673 | — | — | 0 |
| 37262 | 37262 - Intravascular lithotripsy(ies), iliac vascular territory | $26,231 | $19,673 | — | — | 0 |
| 37267 | 37267 REVASC ENDOVASC FPVT STENT SF 1 | $26,231 | $19,673 | — | — | 0 |
| 37269 | 37269 REVASC ENDOVASC FPVT SF CPLX 1 | $26,231 | $19,673 | — | — | 0 |
| 37280 | 37280 REVASC ENDOVASC TPVT ANGIO SF 1 | $26,231 | $19,673 | — | — | 0 |
| 37282 | 37282 REVASC ENDOVASC TPVT CPLX EA | $26,231 | $19,673 | — | — | 0 |
| 37296 | 37296 - REVASC ENDOVASC INFRAMALLEOLAR ANGIO SF 1 | $26,231 | $19,673 | — | — | 0 |
| 37298 | 37298 - REVASC ENDOVASC INFRAMALLEOLAR ANGIO CPLX 1 | $26,231 | $19,673 | — | — | 0 |
Showing top 50 of 2,910 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.